<?xml version="1.0" encoding="UTF-8"?>
<p>At present, ART derivatives are recommended as antimalarial treatments in combination with another molecule with a different mechanism of action and longer half-life (ART combination therapy, ACT) to avoid the onset of resistance and to prevent recrudescence. One of these combinations, AS plus amodiaquine (AQ), was tested against HCMV in a clinical study conducted on 494 Ugandan children treated for acute malaria either with the ACT or with sulfadoxineâ€“pyrimethamine plus AQ. No measurable difference was observed in either the HCMV detection frequency or load in the blood of children in the two groups [
 <xref rid="B49-microorganisms-08-00085" ref-type="bibr">49</xref>].
</p>
